Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025.
Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with the company. Dr. Maltzman will lead Adicet’s clinical development strategy to advance its robust autoimmune and oncology pipeline.
“We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the clinical development of multiple products across therapeutic areas notably in solid tumors and autoimmune diseases, from early-stage research to global approvals and commercialization, will be a big asset for Adicet as we advance our novel pipeline of allogeneic gamma delta CAR T cell therapies for multiple autoimmune and oncology indications,” said Chen Schor, president and CEO of Adicet Bio.
“We’re at an exciting point where we are seeing significant momentum in our clinical trial enrollment efforts, with an increasing number of sites activated and patients enrolling in both the ADI-001 and ADI-270 programs. This progress highlights the promising potential of our therapies. Julie’s expertise will help position us well in our goal for continued success in the development and regulatory progress of these novel therapies for patients,” Mr. Schor added.
Dr. Maltzman commented, “I am extremely honored and privileged to join the Adicet team during this pivotal time in the company’s growth trajectory. Having worked on the development of several transformative therapies, I believe Adicet’s novel allogeneic gamma delta CAR T cell platform has life-changing potential for patients with various oncologic and autoimmune diseases. I am inspired by the opportunity to help lead our efforts to bring these therapies in development to the many patients around the globe who are in dire need of a potential new curative treatment approach.”
